Table 2. Summary of patients treated with the therapeutic system described.
| Patient | History, evaluation | Diagnosis | Status |
|---|---|---|---|
| 67F 3/3 | 2yr memory ⇓; FH+ | aMCI | Normal x 2.5 yrs; working |
| 69M 4/3 | 12yr memory ⇓; FDG-PET+, NPsych+ | Early AD | “Clearly improved;” working |
| 70M 4/3 | 4yr memory ⇓; NPsych+, failed MemTrax | AD | Improved; MemTrax passed |
| 75M 3/3 | 1yr memory ⇓ | SCI | Improved; working |
| 75F C677T | 1yr memory ⇓ | aMCI/early AD | Improved |
| 55F 3/3 | 4yr memory ⇓ | aMCI/early AD | Normal; working |
| 72M 3/3 | 7yr memory ⇓ | aMCI | Improved; working |
| 55M 4/3 | 2yr memory ⇓ | SCI | Normal; working |
| 63F 4/3 | FH dementia, mild memory ⇓ | SCI | Normal, negative amyloid PET; working |
| 60F 4/3 | 4yr rapid decline; MoCA 6, amyloid PET+ | Late AD | Decline |
F, female; M, male; 3/3, ApoE 3/3; 4/3, ApoE 4/3; C677T, the C677T mutation in methylene tetrahydrofolate reductase (MTHFR); FH, family history; aMCI, amnestic mild cognitive impairment; SCI, subjective cognitive impairment; FDG-PET+, fluorodeoxyglucose positron emission tomography interpreted as typical of Alzheimer's disease; amyloid PET+, amyloid PET scan read as abnormal, indicative of amyloid accumulation; NPsych+, quantitative neuropsychology tests showing abnormalities typical of AD; MoCA, Montreal Cognitive Assessment; MemTrax, an iPhone application that quantitates memory.